Jasper Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
39.6%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$2.41next fiscal year
Monitoring Framework
Key Performance Indicators
Briquilimab BEACON Phase 1b/2a Complete Response Rate (Week 3) Quarterly83.0%Target: Maintain high complete response rates in larger cohorts
Briquilimab BEACON Phase 1b/2a Complete Response Rate (Week 12) Quarterly67.0%Target: Demonstrate durable disease control
Cash and Cash Equivalents Quarterly14.1MTarget: Secure additional funding to enable Phase 2b commencement
Watch Items
- Strategic Alternatives Review ProcessTrigger: Announcement of asset sale, licensing, merger, or orderly wind-downAction: Evaluate transaction terms and impact on shareholder value
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price remains below $1.00Action: Monitor bid price ahead of the November 30, 2026 deadline; consider reverse stock split
- Phase 2b CSU Trial CommencementTrigger: Securing necessary capital to initiate the trialAction: Track FDA protocol updates and clinical site readiness
Research as of 19 Jun 2026